Abstract
Major hallmarks of Alzheimers disease (AD) include brain deposition of the amyloid-β peptide (Aβ), which is proteolytically cleaved from a large Aβ precursor protein (APP) by β and β- secretases. A transmembrane aspartyl protease, β-APP cleaving enzyme (BACE1), has been recognized as the β-secretase. We review the structure and function of the BACE1 protein, and of 4129 bp of the 5-flanking region sequence of the BACE1 gene and its interaction with various transcription factors involved in cell signaling. The promoter region and 5-untranslated region (UTR) contain multiple transcription factor binding sites, such as AP-1, CREB and MEF2. A 91 bp fragment is the shortest region with significant reporter gene activity and constitutes the minimal promoter element for BACE1. The BACE1 promoter contains six unique functional domains and three structural domains of increasing sequence complexity as the “ATG” start codon is approached. Notably, the BACE1 gene promoter contains basal regulatory elements, inducible features and sites for regulation by various important transcription factors. Herein, we also discuss and speculate how the interaction of these transcription factors with the BACE1 promoter can modulate synaptic plasticity, neuronal apoptosis and oxidative stress, which are pertinent to the pathogenesis and progression of AD.
Keywords: mRNA EXPRESSION, inflammation, BACE1 homologue, cAMP response element-binding (CREB) sites, chloramphenicol acetyltransferase (CAT) reporter
Current Alzheimer Research
Title: Taking Down the Unindicted Co-Conspirators of Amyloid β-Peptidemediated Neuronal Death: Shared Gene Regulation of BACE1 and APP Genes Interacting with CREB, Fe65 and YY1 Transcription Factors
Volume: 3 Issue: 5
Author(s): Debomoy K. Lahiri, Yuan-Wen Ge, Jack T. Rogers, Kumar Sambamurti, Nigel H. Greig and Bryan Maloney
Affiliation:
Keywords: mRNA EXPRESSION, inflammation, BACE1 homologue, cAMP response element-binding (CREB) sites, chloramphenicol acetyltransferase (CAT) reporter
Abstract: Major hallmarks of Alzheimers disease (AD) include brain deposition of the amyloid-β peptide (Aβ), which is proteolytically cleaved from a large Aβ precursor protein (APP) by β and β- secretases. A transmembrane aspartyl protease, β-APP cleaving enzyme (BACE1), has been recognized as the β-secretase. We review the structure and function of the BACE1 protein, and of 4129 bp of the 5-flanking region sequence of the BACE1 gene and its interaction with various transcription factors involved in cell signaling. The promoter region and 5-untranslated region (UTR) contain multiple transcription factor binding sites, such as AP-1, CREB and MEF2. A 91 bp fragment is the shortest region with significant reporter gene activity and constitutes the minimal promoter element for BACE1. The BACE1 promoter contains six unique functional domains and three structural domains of increasing sequence complexity as the “ATG” start codon is approached. Notably, the BACE1 gene promoter contains basal regulatory elements, inducible features and sites for regulation by various important transcription factors. Herein, we also discuss and speculate how the interaction of these transcription factors with the BACE1 promoter can modulate synaptic plasticity, neuronal apoptosis and oxidative stress, which are pertinent to the pathogenesis and progression of AD.
Export Options
About this article
Cite this article as:
Lahiri K. Debomoy, Ge Yuan-Wen, Rogers T. Jack, Sambamurti Kumar, Greig H. Nigel and Maloney Bryan, Taking Down the Unindicted Co-Conspirators of Amyloid β-Peptidemediated Neuronal Death: Shared Gene Regulation of BACE1 and APP Genes Interacting with CREB, Fe65 and YY1 Transcription Factors, Current Alzheimer Research 2006; 3 (5) . https://dx.doi.org/10.2174/156720506779025224
DOI https://dx.doi.org/10.2174/156720506779025224 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Melatonin in Cardiac Ischemia/Reperfusion-Induced Mitochondrial Adaptive Changes
Cardiovascular & Hematological Disorders-Drug Targets Signal Transduction via Cannabinoid Receptors
CNS & Neurological Disorders - Drug Targets Application of BRET for Studying G Protein-Coupled Receptors
Mini-Reviews in Medicinal Chemistry Neuroimmune Crosstalk in CNS Disorders: The Histamine Connection
Current Pharmaceutical Design Recent Developments in Anti-dotes Against Anthrax
Recent Patents on Anti-Infective Drug Discovery Emerging Targets for the Pharmacological Treatment of Depression: Focus on Melatonergic System
Current Medicinal Chemistry Type I Interferons: Ancient Peptides with Still Under-Discovered Anti-Cancer Properties
Protein & Peptide Letters Nitric Oxide and Schizophrenia: Present Knowledge and Emerging Concepts of Therapy
CNS & Neurological Disorders - Drug Targets Nanotherapeutics in Neuropathologies: Obstacles, Challenges and Recent Advancements in CNS Targeted Drug Delivery Systems
Current Neuropharmacology The Many Faces of Aβ: Structures and Activity
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Implication of CD154/CD40 Interaction in Healthy and Autoimmune Responses
Current Immunology Reviews (Discontinued) Cancer Cell Cannibalism: A Primeval Option to Survive.
Current Molecular Medicine Potential Application of Dietary Polyphenols from Red Wine to Attaining Healthy Ageing
Current Topics in Medicinal Chemistry Tackling the Elusive Challenges Relevant to Conquering the 100-Plus Year Old Problem of Alzheimer’s Disease
Current Alzheimer Research Copper and Heme-Mediated Abeta Toxicity: Redox Chemistry, Abeta Oxidations and Anti-ROS Compounds
Current Topics in Medicinal Chemistry Emerging Potential of Natural Products as an Alternative Strategy to Pharmacological Agents Used Against Metabolic Disorders
Current Drug Metabolism PEDF & Stem Cells: Niche vs. Nurture
Current Drug Delivery Current Drug Targets for Antihyperlipidemic Therapy
Mini-Reviews in Medicinal Chemistry CD38 as a Regulator of Cellular NAD: A Novel Potential Pharmacological Target for Metabolic Conditions
Current Pharmaceutical Design Immunological Aspects of the Prostate Gland and Related Diseases
Current Immunology Reviews (Discontinued)